HBM contact: Dr Ivo Staijen, Dr Emil Bujak
Company status: public
develops breakthrough protein therapeutics using an expanded genetic code which
is harnessed for site specific conjugation with proprietary linkers, payloads
and pharmacokinetic extenders. This gives rise to a single molecular
species that is optimized for safety, efficacy and biophysical properties.
Using this proprietary technology Ambrx can optimize any protein or antibody to
create potentially best-in-class therapeutics such as long-acting proteins,
bi-specifics and antibody drug conjugates. This allows for a safe and effective
targeting of cytotoxic agents or for recruitment of effector functions to tumor
cells (oncology) or for modulation of biological pathways implicated in disease
areas such as autoimmune, metabolic and cardiovascular.